Velphoro® receives EU marketing authorisation for treatment of hyperphosphatemia in adult CKD patients on dialysis
Velphoro® (sucroferric oxyhydroxide) has received EU marketing authorisation from the European Commission for the contro…
Velphoro® (sucroferric oxyhydroxide) has received EU marketing authorisation from the European Commission for the contro…
. - Velphoro® (PA21) recommended for approval in the European Union for the treatment of hyperphosphatemia in adult Chr…
The Galenica Group increased consolidated net sales by 2.0% to CHF 3,359.4 million in 2013, in a market environment char…
The Galenica Group performed well in a complex market environment during the first six months of 2013. Net sales increas…
The Galenica Group recorded profit growth for the 17th consecutive year in 2012: consolidated net profit rose 13.6% to C…
. - Promising Phase II study results with pipeline product PA21 - Phase III study to start soon in collaboration with F…
2009 was a pivotal year for Galenica. The Group made huge investments to prepare for the future: two strategically impor…
The net profit of the Galenica Group reached CHF 189.4 million in 2008, an increase of 40.4% This was the thirteenth con…
The Galenica Group has posted very pleasing results for the first half of 2007: with net sales of CHF 1,236.0 million (+…